Atrium Therapeutics Inc (RNA) — Titan Protect Analysis

RNA

Atrium Therapeutics Inc

Healthcare · ·

$11.80

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$210M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.04

Based on estimated future earnings — lower means cheaper

Rev Growth

+1,148.3%

Year-over-year revenue change

Profit Margin

-160.0%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$25.00

+112% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Atrium Therapeutics Inc

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac disea

https://atriumtherapeutics.com

Country: United States Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-1.163

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1409

No positive edge detected — the data suggests staying out

Calmar Ratio

-1.854

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-49.0%

Historical annualised return based on price data

Max Drawdown

-26.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$16.77

30% below the year high

52W Low

$11.95

-1% above the year low

Avg Volume

482,014

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.02

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.15

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-32.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-88.0%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$37M

Total revenue over the last 12 months

Net Income

$-58,685,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$25.00

Target Median

$25.00

Target Low

$25.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
8 May2026	Dave McCormick	Republican	buy	500K–1M
24 Apr2026	Josh Gottheimer	Democrat	sell	1K–15K
2026-05-08	Dave McCormick	Republican	Purchase	500K–1M
2026-04-24	Josh Gottheimer	Democrat	Sale	1K–15K
2026-04-24	Ro Khanna	Democrat	Purchase	15K–50K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go